Announcement PDF ASX Announcement – 28 October 2026 Resonance Health Ltd ABN: 96 006 762 492 141 Burswood Road, Burswood, WA 6100, AUSTRALIA Postal: PO Box 108, Victoria Park, WA 6979, AUSTRALIA www.resonancehealth.com T + 61 8 9286 5300 info@resonancehealth.com MRI LIVER FIBROSIS DEVICE CLINICAL TRIAL PRELIMINARY RESULTS WEBINAR Resonance Health Ltd (Resonance or Company) (ASX: RHT) has today released “Preliminary results of MRI Liver Fibrosis Device clinical trial investor presentation”, enclosed with this announcement. Investors are invited to join a webinar hosted by Andrew Harrison, MD & CEO and Dr Wenjie Pang, Chief Scientific Officer on Wednesday 28th October 2026 at 10:00 a.m. Australian Western (Perth) Time (AWST). Andrew Harrison, MD & CEO said; “I invite you to join us for the release of our positive preliminary results from our MRI liver fibrosis device clinical trial as we talk though the trial, methods and key outcomes”. You can attend via the link: https://investors.resonancehealth.com/webinars/yEMgGy-mri-liver-fibrosis-device-clinical- trial-preliminary-results-webinar Additionally, a video recording of the presentation will be available within 24 hours following the presentation at the Resonance Health Investor Centre homepage: https://investors.resonancehealth.com/ This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Limited. For further information: Andrew Harrison Managing Director E: andrewh@resonancehealth.com P: +61 8 9286 5300 P R EL I M I NA R Y EP O C ST U D Y R E S UL T S | O C T OB E R 20 2 6 Liver fibrosis results open GLP-1 biomarker opportunity FibrosisAssessment: non-invasive MRI liver fibrosis software as a medical device Andrew Harrison | MD & CEO Dr Wenjie Pang | Chief Scientific Officer Resonance Health Ltd (ASX:RHT) Non-Invasive MRI Liver Fibrosis Device | Preliminary EPoC Study Results | October 2026 IM P O R T AN T NO T I CE Important notice and disclaimer Preliminary results. Liver fibrosis results are preliminary and not yet independently verified, based on 50 subjects from a single site representing a broad spectrum of clinical conditions including liver cancer, and may change as additional data becomes available. FibrosisAssessment is investigational and not cleared for clinical use in any jurisdiction. Compiled by. The extended proof-of-concept (EPoC) study was performed by Dr Wenjie Pang, Chief Scientific Officer of Resonance Health. Dr Pang’s qualifications and experience are set out at www.resonancehealth.com/board-leadership. Comparisons. Comparisons with other tests draw on published studies in different cohorts and are indicative only. No head-to-head study has been performed. Market estimates and economics. Market sizes, pricing, trial sizes and scan volumes are illustrative Company estimates built from the sources shown. They are not forecasts. FY27 guidance excludes revenues that may accrue from the fibrosis device. Forward-looking statements. This presentation contains forward- looking statements that involve risks and uncertainties; actual outcomes may differ materially. See the full disclaimer at the end of this presentation. Not advice. This presentation does not take into account the objectives, financial situation or needs of any person. Investors should seek independent professional advice. 2 Non-Invasive MRI Liver Fibrosis Device | Preliminary EPoC Study Results | October 2026 A T A G L A N C E A fibrosis signal from standard MRI Preliminary EPoC read-out: 50 biopsy-confirmed subjects scanned at 3T, against liver biopsy 0.82 AUROC, significant fibrosis (≥F2) In line with FibroScan (0.82) 93.5% Specificity, advanced fibrosis (≥F3) A rule-in operating point US$0 Added hardware or software at the imaging site 951 Obesity and overweight trials The GLP-1 biomarker opportunity A first-pass model with intentionally limited parameters. Refining it uses data already collected in the study, so no additional data or new study is needed, and every improvement will be validated on independent data. Sources: Company preliminary analysis (n = 50, China site, 3T); Cassinotto et al., Hepatology 2016 (FibroScan); ClinicalTrials.gov via Data Lookout (March 2026). 3 Non-Invasive MRI Liver Fibrosis Device | Preliminary EPoC Study Results | October 2026 01 The opportunity Why liver fibrosis matters in GLP-1, metabolic and obesity trials 4 Non-Invasive MRI Liver Fibrosis Device | Preliminary EPoC Study Results | October 2026 L IV E R F I B RO S I S 101 Fibrosis stage is what trials and payers need to know F0 No fibrosis F1 Portal or perisinusoidal F2 Portal and periportal F3 Bridging fibrosis F4 Cirrhosis Significant fibrosis (≥F2) Advanced fibrosis (≥F3) Today: a needle biopsy Liver biopsy remains an imperfect gold standard due to sampling variability, reader variability and procedure burden, highlighting the need for robust non-invasive biomarkers Why it matters Reliable, reproducible, and clinically meaningful non-invasive endpoints can support clinical trial efficacy assessments, reduce dependence on invasive procedures, and strengthen evidence for regulatory decision-making What FibrosisAssessment does Classifies ≥F1, ≥F2 and ≥F3 from standard MRI (PoC and EPoC) Non-invasive, MRI- based without contrast agent or added hardware (investigational). Fibrosis stages simplified from NASH CRN and METAVIR conventions. Sources: Hsu et al., pooled individual-participant analysis, 2019 (mortality and fibrosis stage); LITMUS Imaging Study protocol (biopsy variability). 5 Any fibrosis (≥F1) Non-Invasive MRI Liver Fibrosis Device | Preliminary EPoC Study Results | October 2026 T H E N E E D Biopsy gates MASH trials, and most fail it 70–80% of patients screened for MASH trials fail screening, mostly because the baseline biopsy does not show fibrotic MASH Roughly 2 to 3 in every 10 screened patients enrol Invasive and imprecise Needle biopsy, an imperfect reference standard, carries procedural risk, samples a tiny fraction of the liver and is subject to sampling and reader variability. Regulators are moving In 2025 the FDA accepted the first Letter of Intent to qualify liver stiffness measured by VCTE (FibroScan) as a reasonably likely surrogate endpoint in MASH. MRE was subsequently accepted into the FDA Biomarker Qualification Program, signalling growing support for non-invasive fibrosis endpoints. Sponsors need scale With two MASH drugs FDA-approved now, trials and therapies need a scalable, repeatable, and clinically meaningful fibrosis assessments to support patient selection, endpoint evaluation, and treatment monitoring. Sources: MASH trial screening analysis, PMC11985113; LITMUS Imaging Study protocol; FDA CDER statement, 27 Aug 2025; HCPLive 2025 (semaglutide approval). 6 Non-Invasive MRI Liver Fibrosis Device | Preliminary EPoC Study Results | October 2026 W HY NO W Three structural tailwinds Independent forces converging on the capabilities Resonance Health has spent 20 years building 01 Liver disease prevalence 1.5B+ people living with chronic liver disease 20%+ of the global population; 58M+ new cases a year MASLD affects about one in four adults; demand for screening, trial enrolment and monitoring is structural 02 MASH diagnostics demand 2 FDA-approved MASH therapies since 2024 Resmetirom (2024) and semaglutide (2025): every patient needs or benefits from fibrosis staging and monitoring Payers may require biopsy or a non- invasive test before covering therapy; the biopsy is the bottleneck 03 GLP-1 trial explosion 951 obesity and overweight trials listed 6+ major GLP-1 agents in late-stage trials, expanding into MASH, HFpEF and CKD Sponsors need body composition, not just weight: liver fat, fibrosis, VAT/SAT and muscle Sources: Company FY26 results presentation (liver disease prevalence); HCPLive 2025 (semaglutide approval); payer prior-authorisation criteria; ClinicalTrials.gov via Data Lookout (March 2026). 7 Non-Invasive MRI Liver Fibrosis Device | Preliminary EPoC Study Results | October 2026 T H E G L P - 1 B I OM A R KE R O P P O R T UN I T Y One MRI visit, the full GLP-1 read-out GLP-1, metabolic or obesity trial Standard MRI at each visit Liver fat HepaFatScan® / Smart® CLEARED Liver iron FerriScan® / FerriSmart® CLEARED Liver fibrosis FibrosisAssessment IN DEVELOPMENT VAT / SAT Visceral and subcutaneous fat INVESTIGATIONAL Muscle quality / mass Fat fraction and volume IN DEVELOPMENT Fibrosis is a key endpoint Fibrosis is a key biomarker endpoint in GLP-1, metabolic and obesity trials, particularly following the FDA approvals of resmetirom and semaglutide for MASH in 2024 and 2025, respectively. The scans already happen Many trials already scan the liver with MRI to measure fat. A fibrosis read can be added to the same images, through the same core lab. We are already inside the trial TrialsWest is running multiple GLP-1 and metabolic trials, and the Image Analysis Group alliance gives sponsors global access. One scan, one ISO 13485 core lab, no added hardware at the imaging site Sources: Company; ClinicalTrials.gov via Data Lookout (March 2026); US FDA approval of semaglutide for MASH (2025); IAG announcement (ASX, 17 Sep 2026). FibrosisAssessment is in development and investigational. 8 Non-Invasive MRI Liver Fibrosis Device | Preliminary EPoC Study Results | October 2026 H O W F IB R OS I S AS S E S S ME N T WO R KS Standard MRI in, fibrosis read out The same core-lab model as FerriScan®, HepaFatScan® and others, already used by clinicians and in pharmaceutical trials worldwide. 1 Scan Standard sequences on any modern 1.5T or 3T scanner. No contrast injection, no added hardware, no site software. 2 Upload DICOM images sent securely through the core-lab workflow used for FerriScan® and HepaFatScan®. 3 Analyse Proprietary analysis of the liver’s MRI signal, built on 20 years of iron- and fat-corrected liver MRI. 4 Report Fibrosis classification against biopsy-defined stages. Images are archived, auditable and re-analysable. 9 Non-Invasive MRI Liver Fibrosis Device | Preliminary EPoC Study Results | October 2026 02 The results Preliminary results from the extended proof-of- concept study (EPoC) 10 Non-Invasive MRI Liver Fibrosis Device | Preliminary EPoC Study Results | October 2026 S T U DY D ES I G N DEVIMLA extended study: what was analysed Study 68 adults with biopsy-confirmed chronic liver disease at sites in Malaysia (University of Malaya), China and India (Indian Institute of Liver and Digestive Sciences). Percutaneous biopsy, staged by an experienced pathologist, is the reference. This read-out 50 subjects from the China site, representing a broad spectrum of clinical conditions, including liver cancer. All MRI examinations at 3T. One initial classification model. Endpoints Significant fibrosis (F0–1 vs F2–4) and advanced fibrosis (F0–2 vs F3–4) against biopsy stage. Biopsy stage distribution, n = 50 Significant fibrosis model (≥F2) F0–1: 10 F2–4: 40 Advanced fibrosis model (≥F3) F0–2: 31 F3–4: 18 Plus one borderline case staged F2–3 (lime) 3T is more technically challenging than 1.5T because magnetic susceptibility artefacts are more prevalent. The 2022 proof of concept used 1.5T in a homogeneous NAFLD/NASH population. 11 Development and Validation of Multiparametric MRI for Non-Invasive Measurement of Liver Fibrosis and Activity Non-Invasive MRI Liver Fibrosis Device | Preliminary EPoC Study Results | October 2026 P R E L IM IN A RY RE S U L T S Unlocking fibrosis signal from standard MRI Significant fibrosis (≥F2) 40 F2–4 vs 10 F0–1 0.4 0.6 0.8 1.0 AUC 0.820 95% CI 0.674–0.940 Sensitivity (30/40) 75.0% 95% CI 43.9–93.3% Specificity (8/10) 80.0% 95% CI 66.7–100% Advanced fibrosis (≥F3) 19 F3–4 (incl. one F2–3) vs 31 F0–2 0.4 0.6 0.8 1.0 AUC 0.788 95% CI 0.631–0.908 Sensitivity (11/19) 57.9% 95% CI 42.9–95.5% Specificity (29/31) 93.5% 95% CI 53.3–100% Sensitivity: proportion of biopsy-positive subjects correctly identified. Specificity: proportion of biopsy-negative subjects correctly excluded. AUC: ability to distinguish the two groups across all cut- offs (0.5 = chance, 1.0 = perfect). 95% CI: range likely to contain the true value. DEVIMLA EPoC interim analysis: 50 of 68 enrolled subjects (China site, 3T), first-pass model. Preliminary; subject to further analysis and independent verification. 12 Non-Invasive MRI Liver Fibrosis Device | Preliminary EPoC Study Results | October 2026 IN T E R P R ET A T I ON What the numbers say, and what they don’t yet A real signal The model separates fibrosis stages well above chance, at both thresholds, on 3T data, from a first-pass model with intentionally limited parameters. Expands the 2022 PoC The 2022 PoC (AUC 0.92, n = 27) separated fibrosis from non-fibrosis, including healthy volunteers. The EPoC tests more demanding endpoints in a more diverse population. Small cohort, wide intervals With 10 F0–1 subjects, specificity for ≥F2 rests on few patients. The validation study is sized to narrow these intervals. Strong potential for early-stage fibrosis detection, in line with FibroScan and the 2022 PoC; lifting advanced-fibrosis performance towards MR elastography is the current development focus. Matching it without the hardware investment is the opportunity. Significant fibrosis (≥F2): AUC vs published benchmarks MRE (pooled analysis, n = 230) 0.92 FibroScan (Cassinotto, n = 291) 0.82 Resonance, first pass (n = 50) 0.82 Axis starts at 0.5 (chance). Advanced fibrosis (≥F3): AUC vs published benchmarks MRE (LITMUS, n = 357) 0.91 FibroScan (Cassinotto, n = 291) 0.86 Resonance, first pass (n = 50) 0.79 Iron-corrected T1 (LITMUS) 0.59 Axis starts at 0.5 (chance). Benchmarks: ≥F2 MRE, Hsu et al. 2019, pooled individual-participant analysis of three studies including Park et al., Gastroenterology 2017 (n = 230); ≥F3 MRE and cT1, Pavlides et al., Nat Med 2026 (LITMUS; ≥F2 not reported); FibroScan, Cassinotto et al., Hepatology 2016. Cross-study; indicative only. 13 Non-Invasive MRI Liver Fibrosis Device | Preliminary EPoC Study Results | October 2026 M OD E L DE V E L O P ME N T Towards a greater AUROC, without a new study The current result represents an early stage of model development N O W First-pass model Intentionally limited parameters, 50 subjects at 3T: AUROC 0.82 (≥F2) and 0.79 (≥F3). N E X T Refined model Ongoing analysis and methodological refinements, using data already collected in DEVIMLA, with the full EPoC analysis covering all 68 subjects. T H E N Locked and validated Every improvement evaluated through rigorous validation on independent datasets, then pivotal validation for the FDA submission. No additional data or new study needed. Reworking the model to improve accuracy draws on data already collected in the DEVIMLA study. Validation of the final, locked model for regulatory submission then follows the FDA pathway set out later in this presentation. 14 Non-Invasive MRI Liver Fibrosis Device | Preliminary EPoC Study Results | October 2026 03 Where it sits Access, positioning and the market opportunity 15 Non-Invasive MRI Liver Fibrosis Device | Preliminary EPoC Study Results | October 2026 P O S IT I ON I NG FibrosisAssessment versus MRE and FibroScan FibrosisAssessment (MRI) MR elastography (MRE) FibroScan (VCTE) Added equipment at site None: standard MRI sequences Driver hardware, sequence and software licence Dedicated ultrasound device and probes Capex per site US$0 ~US$75k–150k per scanner ~US$70k–125k per device Availability Any modern 1.5T or 3T MRI (~50,000 worldwide) ~1,800 sites worldwide Specialist clinics, trained operator at each site Operator dependence Central core-lab analysis Operator-dependent Operator-dependent Known limits Investigational; validation pending Fails with liver iron overload, unreliable in severe obesity, inflammation and ascites Fails with liver iron overload, unreliable in severe obesity, inflammation and ascites Images for central re- read Yes, archived DICOM Yes No anatomical images captured Evidence today (AUROC) Preliminary: 0.82 (≥F2), 0.79 (≥F3); n = 50 0.92 (≥F2, pooled); 0.91 (≥F3, LITMUS) 0.82 (≥F2), 0.86 (≥F3), Cassinotto; FDA letter of intent accepted 2025 Sources: Resoundant; Post-Bulletin and Company (MRE cost); published estimate and Company (FibroScan cost); Diagnostic Imaging (MRE and iron); AJR 2015 (VCTE limits); Hsu et al. 2019; Pavlides et al., Nat Med 2026; Cassinotto et al., Hepatology 2016; FDA CDER, Aug 2025. Cross-study comparisons are indicative only. 16 Non-Invasive MRI Liver Fibrosis Device | Preliminary EPoC Study Results | October 2026 A C CE S S A N D C A PE X Mass access at zero capex for imaging sites ~50,000 MRI scanners worldwide ~1,800 sites offering MRE Circle areas to scale. US$0 FibrosisAssessment: no added hardware or software at the imaging site US$75k–150k MRE: per scanner, for driver hardware, sequence and software licence US$70k–125k FibroScan: per device, plus a trained operator at each site Machine-agnostic by design: standard sequences on existing 1.5T and 3T scanners, delivered through the Company’s ISO 13485-certified core lab. Sources: StartUs Insights (MRI base, 2022 est.); Resoundant (MRE sites); Post-Bulletin and Company (MRE cost); published estimate and Company (FibroScan cost). 17 Non-Invasive MRI Liver Fibrosis Device | Preliminary EPoC Study Results | October 2026 T H E G L P - 1 I M AG I NG PR O T O C OL FibrosisAssessment completes the liver read-out Metabolic and obesity MRI trial endpoints, grouped by region, from one imaging session and one ISO 13485 core lab HEART Paracardiac fat epicardial + pericardial volume IN DEV Cardiac iron (CardiacT2*) septal T2* CLEARED LIVER Liver PDFF (HepaFatScan) ≥30% fall = responder CLEARED VLFF and steatosis grade volumetric fraction CLEARED Liver fibrosis (FibrosisAssessment) vs biopsy IN DEV Liver stiffness (MRE) kPa IN TRIALS Liver volume context for fat change OFFERED Liver iron (FerriScan) reference LIC CLEARED PANCREAS, SPLEEN AND KIDNEYS Pancreatic PDFF ectopic fat; T2D substudies OFFERED Pancreas and spleen volume organ morphology OFFERED Kidney PDFF, renal sinus fat renal risk IN DEV WHOLE BODY Total adipose tissue neck-to-knee fat IN DEV Total lean tissue lean preservation IN DEV Body-fat z-scores vs matched reference IN DEV ABDOMINAL FAT Visceral fat (VAT) whole-abdomen volume IN TRIALS Abdominal SAT central vs subcutaneous IN TRIALS MUSCLE Thigh muscle volume quantity beyond DXA NEW Thigh muscle fat infiltration muscle quality NEW Thigh subcutaneous fat peripheral response NEW Muscle groups, erector spinae localised effects IN DEV Composite muscle score quantity + quality IN DEV STATUS CLEARED Regulatory-cleared IN TRIALS In use in trials OFFERED Offered for trials NEW Newly developed IN DEV In development 18 Non-Invasive MRI Liver Fibrosis Device | Preliminary EPoC Study Results | October 2026 S T R AT E G Y Three markets, entered in sequence STAGE 1 | NOW Clinical trials Investigational use in pharma MASH, GLP-1 and obesity trials. No FDA clearance or reimbursement needed, and it builds the FDA dataset needed for clearance. Paid by sponsors, per scan STAGE 2 | POST-CLEARANCE Clinical diagnostics Launch through hepatology centres and the imaging sites globally already using FerriScan® and HepaFatScan®. Paid by providers, patients and some payers STAGE 3 | POST-COVERAGE Reimbursed diagnostics Payer coverage, naming in MASH- drug prior-authorisation criteria alongside VCTE and MRE, then a Category I CPT code. Paid by insurers, at population scale US context: ~460,000 diagnosed F2–F3 MASH patients under specialist care; 6.7M adults with MASH and ≥F2 fibrosis; 267 MASH trials recruiting. Sources: Madrigal Q2 2026 call; Le et al., JAMA Netw Open 2025; ClinicalTrials.gov via Data Lookout (May 2026). Stage timing depends on FDA clearance and payer decisions. 19 Non-Invasive MRI Liver Fibrosis Device | Preliminary EPoC Study Results | October 2026 E C ON O M IC S Illustrative investigational-use economics per trial Revenue = price per scan × patients × MRI visits Indicative economics for three prevalent trial types Trial type Patients MRI visits Scans Revenue at US$900–1,500* Paired biopsy cases Phase 2b MASH 250 4 1,000 US$0.9M–1.5M ~465 Phase 3 MASH 1,000 4 4,000 US$3.6M–6.0M ~1,860 Obesity trial, liver sub-study 300 3 900 US$0.8M–1.4M – * Price per scan Excludes trial management, data management, reporting and other fees routinely charged to sponsors $0.9M $3.6M $0.8M $1.5M $6.0M $1.4M Phase 2b MASH Phase 3 MASH Obesity + liver Revenue per trial (US$M) At US$900 per scan At US$1,500 per scan Illustrative assumptions, not forecasts. Pricing range per Company; trial sizes and visit schedules vary by sponsor. Paired cases assume biopsy at baseline and end of treatment with ~86% completion. FY27 guidance includes no fibrosis device revenue. 20 Non-Invasive MRI Liver Fibrosis Device | Preliminary EPoC Study Results | October 2026 04 Path to FDA Twenty years of SaMD development and regulatory clearance 21 Non-Invasive MRI Liver Fibrosis Device | Preliminary EPoC Study Results | October 2026 T R A CK R E C O RD Twenty years of SaMD development and clearance FibrosisAssessment follows the path Resonance has taken with its regulatory-cleared SaMDs FerriScan® CLEARED Core-lab liver iron concentration; internationally recognised as the gold standard in LIC assessment FerriSmart® CLEARED AI-trained, automated real-time liver iron, calibrated against FerriScan® HepaFatScan® CLEARED Reliable non-invasive assessment of liver fat for confirmed or suspected fatty liver disease HepaFatSmart® CLEARED AI-trained, automated real-time multi- metric assessment of liver fat LiverSmart® CLEARED Liver iron and liver fat combined in one consolidated report CardiacT2* CLEARED The most widely accepted MRI method for assessing heart iron loading Cleared in the USA, Europe, the UK and Australia | ISO 13485 certified | FibrosisAssessment follows the same pathway Regulatory-cleared SaMD products, some of which incorporate AI. ISO 13485 certification covers the design and manufacture of medical devices. 22 Non-Invasive MRI Liver Fibrosis Device | Preliminary EPoC Study Results | October 2026 R E GU L A T O R Y P A T HW A Y From preliminary results to an FDA submission 1 Complete the EPoC All 68 subjects, independent pathology review, cross-validated results. 2 Model v2 Refine on data already collected; lock the pipeline. 3 FDA Pre- Submission Agree intended use, pathway, reference standard and validation design. 4 Investigational use Paid analysis in sponsor trials; paired MRI–biopsy cases. 5 Pivotal validation Locked model on sequestered cases, independent reads. 6 Submit and clear FDA Biomarker Qualification Program or 510(k), or De Novo if the FDA requires. We are here Capital-light by design: model development, the FDA Pre-Submission and the regulatory files are funded from the balance sheet, while sponsors pay for the scans that build the validation dataset, at US$900–1,500 per scan. Subject to FDA feedback. FDA review goals: Pre-Submission feedback 70 days; 510(k) 90 FDA days; De Novo 150 FDA days. 23 Non-Invasive MRI Liver Fibrosis Device | Preliminary EPoC Study Results | October 2026 C A T AL Y S T S What to watch over the next 12 to 24 months FibrosisAssessment Full EPoC analysis results for all 68 enrolled subjects Model refinement built on data already collected and evaluated on independent data FDA Pre-Submission feedback intended use, pathway, reference standard and validation design First investigational-use contracts paid fibrosis analysis in sponsors’ trials The GLP-1 imaging protocol Muscle quality endpoints to market completing the obesity-trial imaging protocol VAT/SAT automation live more throughput and margin on body-fat reads First Image Analysis Group work orders pilot studies through the global imaging partner (ASX, 17 Sep 2026) Catalysts and timing are not guaranteed. 24 Non-Invasive MRI Liver Fibrosis Device | Preliminary EPoC Study Results | October 2026 IN T HE I R W OR D S A very encouraging step, with a clear path to improve “These preliminary results are a very encouraging step towards commercialising the FibrosisAssessment device in GLP-1 clinical trials. Separating fibrosis stages this well in a challenging, heterogeneous cohort, on 3T data where artefacts are more prevalent, from a first-pass model with intentionally limited parameters is a strong start. Importantly, we now have a baseline to improve the model accuracy using data we already hold, without another trial.” Andrew Harrison Managing Director & CEO “A clear fibrosis signal was identified at 3T consistent with the 1.5T proof-of-concept result, despite the more demanding field strength, in a broad and clinically diverse cohort, using a simple first-pass model with intentionally limited parameters. We see believe potential to further enhance performance through ongoing analysis and methodological refinements of the study data, with every improvement evaluated through rigorous validation on independent datasets.” WP Dr Wenjie Pang Chief Scientific Officer Quotes from the ASX announcement “Liver Fibrosis Results Open Up GLP-1 Biomarker Opportunity”, 27 October 2026. 25 Non-Invasive MRI Liver Fibrosis Device | Preliminary EPoC Study Results | October 2026 K E Y R IS K S Key risks Clinical validation: Preliminary results may not be confirmed in the full and final EPoC analysis or in validation. Model refinement: Planned refinements may not improve performance as expected. Regulatory: The FDA pathway (510(k) or De Novo), timing and outcome are uncertain; the FDA may require more data. Data rights: The validation dataset depends on sponsors agreeing to the use of paired MRI–biopsy data. Commercial adoption: Sponsors may not adopt an investigational fibrosis read, or may prefer established tests. Reimbursement: There is no assurance of coding, coverage or payment for diagnostic use. Competition: MRE, VCTE and other MRI methods compete, and may improve. People: Performance depends on retaining key scientific and commercial staff. Not an exhaustive list. Investors should consider all information in this presentation, including the forward-looking statements, and seek professional advice. 26 Non-Invasive MRI Liver Fibrosis Device | Preliminary EPoC Study Results | October 2026 Summary 1 A real fibrosis signal from standard MRI: AUROC 0.82 for ≥F2, in line with FibroScan, and 0.79 for ≥F3. 2 Achieved at 3T in a challenging, heterogeneous cohort, from a first-pass model. 3 Refinement uses data already collected: no additional data or new study needed. 4 No hardware at the scanner: built for GLP-1, metabolic and obesity trials that already scan the liver. 5 Trials first, then diagnostics, then reimbursement, on a 20-year SaMD track record. Andrew Harrison, Managing Director & CEO andrewh@resonancehealth.com | +61 8 9286 5300 investors.resonancehealth.com 27 Non-Invasive MRI Liver Fibrosis Device | Preliminary EPoC Study Results | October 2026 A P P EN D IX Glossary AUROC (AUC) Area under the ROC curve: ability to separate two groups across all cut-offs (0.5 = chance, 1.0 = perfect). Sensitivity Proportion of biopsy-positive subjects the model correctly identifies. Specificity Proportion of biopsy-negative subjects the model correctly rules out. 95% CI Confidence interval: the range likely to contain the true value; intervals are typically wider when sample sizes are small. F0–F4 Biopsy fibrosis stage (METAVIR), from none (F0) to cirrhosis (F4). Significant is ≥F2; advanced is ≥F3. MASLD / MASH Metabolic dysfunction-associated steatotic liver disease and steatohepatitis (formerly NAFLD / NASH). GLP-1 GLP-1 receptor agonists: a drug class for obesity and type 2 diabetes, now expanding into MASH. MRE Magnetic resonance elastography: liver stiffness measured with driver hardware and software added to the scanner. VCTE (FibroScan) Vibration-controlled transient elastography: an ultrasound- based liver stiffness device. cT1 Iron-corrected T1: an MRI measure of liver tissue characteristics. 1.5T / 3T MRI field strength in tesla. 3T gives more signal but more susceptibility artefacts. SaMD Software as a medical device: software with a medical purpose, regulated as a device. EPoC / DEVIMLA The extended proof-of-concept stage of Resonance’s DEVIMLA liver fibrosis study. 510(k) / De Novo FDA clearance routes: with a predicate device (510(k)) or for novel low-to-moderate risk devices (De Novo). Investigational use Use of a device in clinical trials before clearance, where results are not used for patient care. 28 FDA Biomarker Qualification Program A formal regulatory pathway that qualifies biomarkers for specific contexts of use (COU) in drug development. Non-Invasive MRI Liver Fibrosis Device | Preliminary EPoC Study Results | October 2026 D IS C L A IM E R Disclaimer and forward-looking statements This presentation has been prepared by Resonance Health Ltd (“Resonance Health” or “Company”) and contains forward-looking statements that are based on current expectations and beliefs and are subject to numerous factors and uncertainties that could cause actual results to differ materially from those described. Forward-looking statements contained in this presentation include statements about future financial and operating results, research and development and regulatory submissions, possible or assumed future growth opportunities, and risks and uncertainties that could affect Resonance Health’s products and services. These forward-looking statements are not guarantees of future performance, involve certain risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may prove inaccurate. Actual outcomes and results may differ materially from what is expressed in any forward-looking statement in which Resonance Health expresses an expectation or belief as to future results. Ther